LMDX News and Press, LumiraDx Limited From 11/10/21

LumiraDx Reports Third Quarter 2021 Financial Results Strong Revenue Growth and Strategic Progress on Platform, Products and Pipeline PR Newswire LONDON , Nov. 10, 2021 /PRNewswire/ -- LumiraDx (Nasdaq:LMDX), a next-generation point of care (POC) diagnos...

LumiraDx to Announce Third Quarter 2021 Financial Results and Host Quarterly Conference Call on November 10 PR Newswire LONDON , Nov. 2, 2021 /PRNewswire/ -- LumiraDx  (Nasdaq:LMDX), a next-generation point of care (POC) diagnostics company, announced it wil...

LumiraDx Announces the Intended Use for its FDA EUA Authorized High Sensitivity COVID-19 Antigen Test has been Expanded to Include Testing of Asymptomatic Individuals - Microfluidic immunofluorescence assay authorized for screening asymptomatic individuals using a single test wi...

LumiraDx ( NASDAQ: LMDX ) has received emergency user approval for the SARS-CoV-2 Antigen test in India from the Central Drugs Standard Organisation. The diagnostic Antigen test is designed to detect antigen nucleocapsid protein from nasal swab, and results are available wit...

4 Health Care Stocks To Check Out In The Stock Market Today Even with the focus on earnings season in the stock market this week, Covid continues to dominate the headlines. Because of this, health care stocks remain relevant regardless. After all, the health care industry is...

LumiraDx (NASDAQ:LMDX) +37% after approval for COVID-19 antigen test in India Troika Media (NASDAQ:TRKA) +32%. Puhui Wealth Investment Management (NASDAQ:PHCF) +16%. Valneva  (NASDAQ:VALN) +16%. Xiaobai Maimai (NASDAQ:HX) +11%. Cyclerion Therapeutics (NASDAQ:CYCN) +11%. F-star ...

LumiraDx receives approval for its COVID-19 Antigen Test for use in India - Test combines sensitivity with speed and is designed to be used in health care settings to aid with rapid diagnosis of COVID-19 - LumiraDx's microfluidic technology and innovative Point of Care (POC)...

LumiraDx Announces FDA EUA Submission for its SARS-CoV-2 & Flu A/B Rapid Antigen Test LumiraDx Announces FDA EUA Submission for its SARS-CoV-2 & Flu A/B Rapid Antigen Test - Rapid microfluidic immunofluorescence assay for use with the LumiraDx Platform intended for t...